Oxford Immunotec Announces Completion of Re-Registration in China for T-SPOT.TB Test

Oxford Immunotec Global PLC

, a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that the company's T-SPOT®.TB test has completed the re-registration process with the China Food and Drug Administration (CFDA). The registration became effective December 11, 2014 and lasts for five years. "We are pleased to have completed re-registration of our T-SPOT.TB test and look forward to continuing to work with our partner Fosun Pharmaceuticals to further grow the adoption of our technology in China," said Dr. Peter Wrighton-Smith. "As the re-registration occurred in line with our expected timing, we do not expect any disruption to our business in China."